11/06/20 6:50 AMNasdaq : AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2020Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2020. ThirdRHEA-AIneutral
10/29/20 4:05 PMNasdaq : AMPHAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2020Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its third quarter of 2020 ended September 30, 2020, before the market opens on Friday, November 6 th, 2020, and will hold a conferenceRHEA-AIneutral
10/06/20 6:00 AMNasdaq : AMPHAmphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate InjectionAmphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration ("FDA") approved the Company's Abbreviated New Drug Application ("ANDA") for Atropine Sulfate injection 0.1mg/mL in the 10 mL Luer-Jet (R)RHEA-AIvery positive
09/03/20 4:05 PMNasdaq : AMPHAmphastar Pharmaceuticals to Present at the Wells Fargo 2020 Virtual Healthcare ConferenceAmphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and ClinicalRHEA-AIneutral
06/19/20 6:05 AMNasdaq : AMPHAmphastar Pharmaceuticals to Present at the BMO Prescriptions for Success Healthcare ConferenceAmphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will be presenting at BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time.RHEA-AIneutral
06/12/20 6:30 AMNasdaq : AMPHAmphastar Pharmaceuticals to Present at the Raymond James Virtual 2020 Human Healthcare Innovation ConferenceAmphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice PresiRHEA-AIneutral
06/09/20 6:00 AMNasdaq : AMPHAmphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose VialAmphastar(R) Pharmaceuticals, Inc., (NASDAQ: AMPH) ("Amphastar"), today announces that the U.S. Food and Drug Administration ("FDA") has approved its Abbreviated New Drug Application ("ANDA") forRHEA-AIpositive
06/02/20 4:05 PMNasdaq : AMPHAmphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare ConferenceAmphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO and Dan Dischner, Vice President of Corporate Communications and Human Resources will be presenting at the JeRHEA-AIneutral
05/07/20 4:05 PMNasdaq : AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2020Reports Net Revenues of $84.7 Million for the Three Months Ended March 31, 2020 Reports Net Revenues of $84.7 Million for the Three Months Ended March 31, 2020RHEA-AIneutral
05/04/20 6:01 AMNasdaq : AMPHAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2020Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2020 ended March 31, 2020, after the market closes on Thursday, May 7th, 20RHEA-AIneutral
